Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ZABETH CATALINA CURE LOPEZ

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1467728733
CMS profile
1381330
Location
PALM SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$20.82

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $20.82 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $20.82 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ZABETH CATALINA CURE LOPEZ

NPI 1467728733 · CMS profile ID 1381330

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

PALM SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467728733?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ZABETH CATALINA CURE LOPEZ, NPI 1467728733, CMS profile ID 1381330. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467728733?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ZABETH CATALINA CURE LOPEZ, NPI 1467728733, CMS profile ID 1381330. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467728733?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ZABETH CATALINA CURE LOPEZ, NPI 1467728733, CMS profile ID 1381330, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1467728733?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $20.82 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $20.8211/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794308781 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $834.21 32
PY2021 $20.82 1
PY2022 $570.90 22
PY2023 $526.25 25
PY2024 $374.12 12
PY2025 $374.31 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $176,791.19 101

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

101 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ARGENX US, INC. $71.00 12/19/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150169
Principal investigator 1 ARGENX US, INC. $315.00 12/19/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150175
Principal investigator 1 ARGENX US, INC. $340.31 12/12/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150131
Principal investigator 1 ARGENX US, INC. $71.00 12/05/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149994
Principal investigator 1 ARGENX US, INC. $139.00 12/05/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150025
Principal investigator 1 ARGENX US, INC. $2,652.00 12/05/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150029
Principal investigator 1 ARGENX US, INC. $84.00 12/05/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150065
Principal investigator 1 ARGENX US, INC. $98.00 12/05/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150069
Principal investigator 1 ARGENX US, INC. $91.00 12/05/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150107
Principal investigator 1 ARGENX US, INC. $88.00 12/05/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150117
Principal investigator 1 ARGENX US, INC. $133.00 12/05/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150120
Principal investigator 1 ARGENX US, INC. $402.00 12/05/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150206
Principal investigator 1 ARGENX US, INC. $336.58 12/01/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150072
Principal investigator 1 ARGENX US, INC. $6,126.00 11/20/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150033
Principal investigator 1 ARGENX US, INC. $885.00 11/20/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150156
Principal investigator 1 ARGENX US, INC. $6,163.00 11/20/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150190
Principal investigator 1 ARGENX US, INC. $6,163.00 11/20/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150193
Principal investigator 1 ABBVIE INC. $17,383.12 11/05/2025 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202522699
Principal investigator 1 ARGENX US, INC. $142.00 10/20/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149989
Principal investigator 1 ARGENX US, INC. $315.00 10/20/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150112
Principal investigator 1 ARGENX US, INC. $210.00 10/20/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150135
Principal investigator 1 ARGENX US, INC. $2,082.00 10/20/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150160
Principal investigator 1 ARGENX US, INC. $2,082.00 10/20/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150163
Principal investigator 1 ARGENX US, INC. $105.00 10/20/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150198
Principal investigator 1 ARGENX US, INC. $105.00 10/20/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150202
Principal investigator 1 ARGENX US, INC. $2,082.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149998
Principal investigator 1 ARGENX US, INC. $2,082.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150003
Principal investigator 1 ARGENX US, INC. $2,082.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150007
Principal investigator 1 ARGENX US, INC. $64.30 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150011
Principal investigator 1 ARGENX US, INC. $1,998.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150015
Principal investigator 1 ARGENX US, INC. $1,998.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150021
Principal investigator 1 ARGENX US, INC. $6,688.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150040
Principal investigator 1 ARGENX US, INC. $6,688.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150047
Principal investigator 1 ARGENX US, INC. $6,688.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150049
Principal investigator 1 ARGENX US, INC. $3,634.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150053
Principal investigator 1 ARGENX US, INC. $3,634.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150057
Principal investigator 1 ARGENX US, INC. $3,634.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150061
Principal investigator 1 ARGENX US, INC. $885.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150076
Principal investigator 1 ARGENX US, INC. $885.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150080
Principal investigator 1 ARGENX US, INC. $885.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150084
Principal investigator 1 ARGENX US, INC. $885.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150089
Principal investigator 1 ARGENX US, INC. $885.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150093
Principal investigator 1 ARGENX US, INC. $885.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150097
Principal investigator 1 ARGENX US, INC. $885.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150100
Principal investigator 1 ARGENX US, INC. $885.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150104
Principal investigator 1 ARGENX US, INC. $6,126.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150124
Principal investigator 1 ARGENX US, INC. $6,126.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150127
Principal investigator 1 ARGENX US, INC. $4,851.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150140
Principal investigator 1 ARGENX US, INC. $4,851.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150144
Principal investigator 1 ARGENX US, INC. $4,851.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150147
Principal investigator 1 ARGENX US, INC. $4,851.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150151
Principal investigator 1 ARGENX US, INC. $2,138.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150180
Principal investigator 1 ARGENX US, INC. $2,138.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150184
Principal investigator 1 ARGENX US, INC. $2,138.00 10/02/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150186
Principal investigator 1 ARGENX US, INC. $424.00 09/03/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150281
Principal investigator 1 ARGENX US, INC. $210.00 09/03/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150285
Principal investigator 1 ARGENX US, INC. $142.00 09/03/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150289
Principal investigator 1 ARGENX US, INC. $210.00 09/03/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150363
Principal investigator 1 ARGENX US, INC. $191.00 09/03/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150371
Principal investigator 1 ARGENX US, INC. $0.70 09/03/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150374
Principal investigator 1 ARGENX US, INC. $1.40 09/03/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150377
Principal investigator 1 ARGENX US, INC. $10,000.00 08/13/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150248
Principal investigator 1 ARGENX US, INC. $2,500.00 08/13/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150252
Principal investigator 1 ARGENX US, INC. $900.00 08/13/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150257
Principal investigator 1 ARGENX US, INC. $1,800.00 08/13/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150268
Principal investigator 1 ARGENX US, INC. $2,000.00 08/13/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150273
Principal investigator 1 ARGENX US, INC. $1,500.00 08/13/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150278
Principal investigator 1 ARGENX US, INC. $1,342.00 08/13/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150341
Principal investigator 1 ARGENX US, INC. $133.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150262
Principal investigator 1 ARGENX US, INC. $71.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150294
Principal investigator 1 ARGENX US, INC. $98.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150299
Principal investigator 1 ARGENX US, INC. $91.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150305
Principal investigator 1 ARGENX US, INC. $84.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150311
Principal investigator 1 ARGENX US, INC. $139.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150314
Principal investigator 1 ARGENX US, INC. $133.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150318
Principal investigator 1 ARGENX US, INC. $98.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150322
Principal investigator 1 ARGENX US, INC. $91.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150326
Principal investigator 1 ARGENX US, INC. $84.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150329
Principal investigator 1 ARGENX US, INC. $112.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150333
Principal investigator 1 ARGENX US, INC. $139.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150337
Principal investigator 1 ARGENX US, INC. $402.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150344
Principal investigator 1 ARGENX US, INC. $402.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150348
Principal investigator 1 ARGENX US, INC. $88.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150352
Principal investigator 1 ARGENX US, INC. $71.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150355
Principal investigator 1 ARGENX US, INC. $112.00 08/07/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150359
Principal investigator 1 ABBVIE INC. $4,220.78 08/06/2025 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202503133
Principal investigator 1 ARGENX US, INC. $382.00 08/04/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150367
Principal investigator 1 ARGENX US, INC. $382.00 08/04/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150381
Principal investigator 1 ARGENX US, INC. $2.80 08/04/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150384
Principal investigator 1 ARGENX US, INC. $2.80 08/04/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150387
Principal investigator 1 ARGENX US, INC. $95.50 08/04/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150391
Principal investigator 1 ARGENX US, INC. $75.20 06/18/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150211
Principal investigator 1 ARGENX US, INC. $71.60 06/18/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150215
Principal investigator 1 ARGENX US, INC. $764.00 06/18/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150218
Principal investigator 1 ARGENX US, INC. $11.20 06/18/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150222
Principal investigator 1 ARGENX US, INC. $51.75 06/18/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150227
Principal investigator 1 ARGENX US, INC. $106.75 06/18/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150231
Principal investigator 1 ARGENX US, INC. $1.40 06/18/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150235
Principal investigator 1 ARGENX US, INC. $191.00 06/18/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150240
Principal investigator 1 ARGENX US, INC. $159.00 06/18/2025 Non-covered Recipient Entity
Finlay Medical Research Corp
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150243
Principal investigator 1 ABBVIE INC. $13,700.00 05/07/2025 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202483835